Phase 1 N=67 Bioequivalence Study of Tacrolimus in Healthy Volunteers
Healthy Volunteers
Primary: Area Under the Concentration (AUC 72) — 37434.51; 33716.80 pg.h/mL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=36 Bioequivalence Study Coadministered to Healthy Subjects in the Fasted State
Type 2 Diabetes Mellitus
Primary: Saxagliptin Maximum Observed Concentrations (Cmax) — 26.2; 25.5 ng/mL — p=0.4950
Phase 1 N=18 Bioavailability of 3 Different Formulations of BI 207127 in Healthy Male Volunteers
Healthy
Primary: AUC0-∞ — 10600; 12400; 13600 nmol*h/L
N/A N=28 Bioequivalence Study for Mejoral 500 Product
Pain
Primary: Area Under the Curve From Time Zero to Last Sampling Time [AUC(0-t)] — 15.212; 14.698 hours*microgram/millilitre (h*μg/mL)
Phase 1 N=64 A Study in Healthy People to Compare How 2 Different High Dose Formulations of BI 1015550 Are Taken up in the Body
Healthy
Primary: Area Under the Concentration-time Curve of Nerandomilast in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz) — 2275.77; 2166.70…
Phase 1 N=64 A Study in Healthy People to Compare How 2 Different Low Dose Formulations of BI 1015550 Are Taken up in the Body
Healthy
Primary: Area Under the Concentration-time Curve of Nerandomilast in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz) — 1270.92; 1320.24…
Phase 1 N=28 A Bioequivalence Study Comparing A Fixed Dose Combination Formulation, Rin 150 And Individual Reference Drugs In Healthy Volunteers
Healthy Volunteers
Primary: Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) — 85020; 90030; 16220; 16120 (nanogram*hour) per milliliter (ng*h/mL)
Phase 1 N=12 This Study in Healthy Men Tests How the Body Takes up BI 1467335
Healthy
Primary: After the First Dose: Area Under the Concentration-time Curve of BI 1467335 Over the Time Interval From 0 Extrapolated to Infinity (AUC0-infinity) of BI 1467335 (After…
Phase 1 N=84 Clopidogrel Bioequivalence Study in Healthy Subjects
Bioequivalence, AUC, Cmax, Pharmacokinetics
Primary: Pharmacokinetics of Clopidogrel by Assessment of Area Under the Curve From Time Zero Extrapolated to Infinity (AUC(0-inf)) — 1.05; 0.992; 1.09 ng*h/mL
Phase 1 N=32 Bioequivalence Study in Healthy Volunteers for Empagliflozin/Metformin Fixed Dose Combination Compared to Separate Tablets
Healthy
Primary: AUC (0-tz) (Area Under the Concentration-time Curve of Metformin in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point) — 6260; 6360 ng*h/mL…
Phase 1 N=49 A Pharmacokinetic Study Comparing MB02 And EU Avastin® In Healthy Male Volunteers
Healthy Volunteers · Male · Japanese
Primary: Area Under the Serum Concentration-time Curve From Time Zero to Infinity [AUC(0-∞)] — 30200000; 29000000 ng*h/mL
Phase 1 N=6 A Study in Healthy Men to Measure the Amount of BI 425809 in the Blood When Taken as a Tablet
Healthy
Primary: Area Under the Concentration-time Curve of the Analyte ([14C]-BI 425809 After iv Administration as Well as for BI 425809 After Oral Administration) Over the Time…
Phase 1 N=40 Comparative Bioavailability Study of Two Different Sources of Eslicarbazepine Acetate
Epilepsy
Primary: Cmax - Maximum Plasma Concentration — 6461; 13183; 6547; 12988 ng/ml
Phase 1 N=9 This Study in Healthy Men and Women Tests How the Body Takes up BI 409306
Healthy
Primary: Area Under the Concentration-time Curve of BI 409306 and Stable Labelled Isotope BI 409306 (C-13/N-15) Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)…
Phase 1 N=32 Relative Bioavailability and Food Effect Study of CVN424
Parkinson's Disease
Primary: Area Under the Concentration-time Curve From Time 0 to the Time of the Last Measured Non Zero Concentration (AUC0-t) of CVN424 Suspension Fasted and Tablet Fasted…
Phase 1 N=8 A Study in Healthy Men to Test How BI 1015550 is Taken up and Handled by the Body
Healthy
Primary: Dose Normalized Area Under the Concentration-time Curve of BI 1015550 in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-inf) — 118.27; 161.69…
Phase 4 N=16 The Bioequivalence of Atripla in an Oral Liquid Formulation Compared With the Tablet Formulation in Healthy Volunteers
Healthy
Primary: Area Under the Concentration Time Curve for Tenofovir, Emtricitabine and Efavirenz — 58.7; 56.7; 10.9; 10.8 mg*hr/mL — p=<0.05
Phase 1 N=28 Bioequivalence Study in Healthy Subjects, 2*5 mg Tablets Rivaroxaban Versus 1*10 mg Tablet Rivaroxaban
Therapeutic Equivalency
Primary: Area Under the Plasma Concentration Versus Time Curve From Time Zero to Infinity After Single Dose (AUC) Incl. Bioequivalence (BE) Evaluation — 1374; 1268 µg*hr/L…
Phase 1 N=81 Safety of Single Rising Doses and Relative Bioavailability of BI 691751
Healthy
Primary: AUC0-72h (Part II) — 2740; 3050; 2800 nmol*h/L
Phase 1 N=12 A Study in Healthy Men to Test How BI 1358894 is Taken up in the Body and How Food Influences the Amount of BI 1358894 in the Blood
Healthy
Primary: Part 1: Area Under the Concentration-time Curve of BI 1358894 Over the Time Interval From 0 to Infinity After i.v. Administration and After Oral Administration…
Phase 1 N=42 Bioequivalence Study of Oral Suspension and Intravenous Formulation of Edaravone in Healthy Adult Subjects
Healthy Adult Subjects
Primary: Area Under the Plasma Concentration Versus Time Curve From Time Zero up to the Last Quantifiable Concentration Time-point (AUC0-t) of Unchanged Edaravone After Oral and…
Phase 1 N=12 Study Evaluating Absorption, Distribution, Metabolism and Excretion (ADME) of Single Dose [14C]-BI 207127 in Healthy Male Volunteers
Healthy
Primary: AUC0-infinity of Plasma Deleobuvir — 19300 nmol*h/L
Phase 2 N=32 BE Study of Metformin GSK 500mg
Diabetic Foot
Primary: Mean Maximal Measured Plasma Concentration (Cmax) After a Single Dose — 962.728; 985.257 Nanogram per milliltre (ng/mL) — p=0.3125
Phase 1 N=24 Relative Bioavailability of Two Tepotinib Film-Coated Tablet Formulations in Healthy Volunteers
Healthy
Primary: Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Sampling Time (AUC0-t) at Concentration at or Above Lower Limit of Quantitation (LLOQ) of…
Phase 1 N=6 A Study in Healthy Men to Measure the Amount of BI 730357 in the Blood When Taken as a Tablet
Healthy
Primary: Area Under the Concentration-time Curve of BI 730357 Over the Time Interval From 0 to Infinity (Dose Normalized). — NA; NA mmol*h/L/kg
Phase 1 N=12 Comparative Bioavailability Study of BIA 9-1067 25 mg Capsules
Parkinson
Primary: Cmax - Maximum Observed Plasma Concentration — 635.0; 238.2 ng/mL
Phase 1 N=28 Bioequivalence Study of Test and Reference 120 mg Etoricoxib Film-coated Tablets in Healthy Volunteers
Bioequivalence · Healthy Subjects
Primary: Maximum Plasma Concentration (Cmax) — 1948.656; 1916.300 ng/mL
Phase 1 N=114 Pharmacokinetic Study Comparing MB02 And US And EU Avastin® In Healthy Male Volunteers
Healthy Volunteers
Primary: Cmax: Maximum Observed Serum Concentration — 86100; 81100; 87500 (ng/mL)/(mg/mL)
Phase 1 N=22 Mass Balance and Absolute Bioavailability Study of RO7049389 in Healthy Volunteers
Healthy Volunteers
Primary: Percentage of Dose Excreted in Urine - MB Cohort — 3.81 Percentage
Phase 1 N=18 A Study to Evaluate the Tolerability and Pharmacokinetics of Two Single and Multiple High Dose Regimens of BIA 2-093 In Healthy Volunteers
Epilepsy
Primary: Number of Adverse Events Reported — 10; 7; 7 Number of adverse events reported